Stoke Therapeutics granted FDA orphan drug designation for STK-001 for Dravet Syndrome

This article was originally published here

Dravet syndrome is a severe and progressive genetic epilepsy, characterized by frequent, prolonged and refractory seizures beginning within the first year of life. The effects of the disease

The post Stoke Therapeutics granted FDA orphan drug designation for STK-001 for Dravet Syndrome appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply